

BANDARAM PHARMA PACKTECH LIMITED
(Formerly Known as Shiva Medicare Limited)

CIN: L93090KA1993PLC159827

Regd Office: 601,5th Floor, Oxford Towers, Opp. to Leela Palace Hotel, Old Airport Road, Kodihalli, Bangalore - 560008.

Statement of Unaudited Results for the Quarter Ended and Three Months Ended 30.09.2022 (Amount Rs. in lakhs)

S.No.	Particulars	STAND ALONE					CONSOLIDATED						
		For the Quarter ended			Six Months ended		Previous Year	For the Quarter ended			Six Months ended		Previous Year
		30.09.2022 (Unaudited)	30.06.2022 (Unaudited)	30.09.2021 (Unaudited)	30.09.2022 (Unaudited)	30.09.2021 (Unaudited)	31.03.2022 2 (Audited)	30.09.2022 2 (Unaudited)	30.06.2022 (Unaudited)	30.09.2021 1 (Unaudited)	30.09.2022 2 (Unaudited)	30.09.2021 1 (Unaudited)	31.03.2022 2 (Audited)
I.	Revenue from Operations	-	-	-	-	-	-	236.78	90.62	-	327.40	-	-
II.	Other Income	-	-	-	-	-	-	0.03	-	-	0.03	-	-
III.	Total income (I+II)	-	-	-	-	-	-	236.81	-	-	327.43	-	-
IV.	Expenses												
	(a) Cost of Materials consumed	-	-	-	-	-	-	234.37	86.05	-	320.42	-	-
	(b) Purchase of stock-in-trade	-	-	-	-	-	-	-	-	-	-	-	-
	(c) Changes in inventories of finished goods,	-	-	-	-	-	-	50.27	14.83	-	-65.10	-	-
	(d) Employee benefits expenses	0.75	0.50	-	1.25	-	-	24.30	7.70	-	32.00	-	-
	(e) Finance Cost	-	-	-	-	-	0.01	9.82	5.97	-	15.79	-	0.01
	(f) Depreciation and amortisation	-	-	-	-	-	-	24.13	5.32	-	29.45	-	-
	(h) Other expenses	0.34	11.94	-	12.28	-	1.00	19.90	17.10	-	37.00	-	1.00
	Total Expenses	1.09	12.44	-	13.53	-	1.01	262.25	107.31	-	369.56	-	1.01
V.	Profit / (Loss) before and exceptional items and Tax (III-IV)	(1.09)	(12.44)	-	(13.53)	-	(1.01)	(25.44)	(16.69)	-	(42.13)	-	(1.01)
VI.	Exceptional items	-	-	-	-	-	-	-	-	-	-	-	-
VII.	Profit / (Loss) from before tax (V-VI)	(1.09)	(12.44)	-	(13.53)	-	(1.01)	(25.44)	(16.69)	-	(42.13)	-	(1.01)
VIII.	Tax expense												
	Current Tax	-	-	-	-	-	-	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-	-	-	-	-	-	-
IX.	Net Profit / (Loss) for the period from Continuing operations (VII-VIII)	(1.09)	(12.44)	-	(13.53)	-	(1.01)	(25.44)	(16.69)	-	(42.13)	-	(1.01)
X.	Profit / (Loss) from discontinuing	-	-	-	-	-	-	-	-	-	-	-	-
XI.	Tax Expense of discontinuing operations	-	-	-	-	-	-	-	-	-	-	-	-
XII.	Profit/ (Loss) from discontinuing operations after tax	-	-	-	-	-	-	-	-	-	-	-	-
XIII.	Profit/(loss) for the Period (IX+XII)	(1.09)	(12.44)	-	(13.53)	-	(1.01)	(25.44)	(16.69)	-	(42.13)	-	(1.01)
XIV.	Other Comprehensive Incomes												
A)	(i) Items that will not be recycled to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
	(a) Others (gratuity and leave encashment excess provision reversal)	-	-	-	-	-	-	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
B)	(i) Items that may be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
	(ii) Income tax on items that may be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
	Total Comprehensive Income	-	-	-	-	-	-	-	-	-	-	-	-
XV.	Total Comprehensive Income for the	(1.09)	(12.44)	-	(13.53)	-	(1.01)	(25.44)	(16.69)	-	(42.13)	-	(1.01)
XVI.	Earnings Per Equity Share of face value of Rs.10/- each)(for Continuing												
	1) Basic	(0.04)	(0.41)	-	(0.45)	-	(0.03)	(0.85)	(0.56)	-	(1.40)	-	(0.03)
	2) Diluted	(0.04)	(0.41)	-	(0.45)	-	(0.03)	(0.85)	(0.56)	-	(1.40)	-	(0.03)
XVII.	Earnings Per Equity Share of face value of Rs.10/- each) (for Discontinuing												
	1) Basic	(0.04)	(0.41)	-	(0.45)	-	(0.03)	(0.85)	(0.56)	-	(1.40)	-	(0.03)
	2) Diluted	(0.04)	(0.41)	-	(0.45)	-	(0.03)	(0.85)	(0.56)	-	(1.40)	-	(0.03)
XVIII.	Earnings Per Equity Share of face value of Rs.10/- each) (for Continued and Discontinuing operations):												
	1) Basic	(0.04)	(0.41)	-	(0.45)	-	(0.03)	(0.85)	(0.56)	-	(1.40)	-	(0.03)
	2) Diluted	(0.04)	(0.41)	-	(0.45)	-	(0.03)	(0.85)	(0.56)	-	(1.40)	-	(0.03)
XIX.	Paid-up equity share capital (Face Value of Rs. 10/- per share)	300.00	300.00	227.70	300.00	227.70	300.00	300.00	300.00	227.70	300.00	227.70	300.00

Notes:

- In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of the Companies Act, 2013, the above Financial Results have been prepared. The same is reviewed by the Statutory Auditors of Company and recommended by the Audit Committee and subsequently approved by the Board of Directors of Company at their meeting held on 09-11-2022.
- The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS-34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and other accounting pronouncements generally accepted in India.
- The figures of the previous year/periods have been re-grouped/re-classified, wherever necessary, for the purpose of comparison with the current year/period figures.
- The Company has no business operations during the quarter ending 30th September, 2022. Hence, segmentwise report as per Ind AS -108, is not applicable.
- The Company has acquired 55% shareholding in M/s. VSR Paper and Packaging Ltd., Hyderabad. Accordingly, this subsidiary company's quarterly results for the period ending 30th September, 2022, have been disclosed in this Financial Statements.
- The above Financial Results are also available on the company's website www.bandaram.com

For and on Behalf of the Board of Directors
Bandaram Pharma Packtech Limited
(Formerly Known as Shiva Medicare Limited)



B. Muniratnam Reddy
Managing Director
DIN: 09487708

Place : Bangalore
Date : 9-11-2022

Bandaram Pharma Packtech Limited
(Formerly Known as Shiva Medicare Limited)
CIN: L93090KA1993PLC159827

Regd Office: 601,5th Floor, Oxford Towers, opp to Leela Palace Hotel, Old Airport Road, Kodihalli
Bangalore - 560008

Statement of Stand Alone Financial Position as at September 30, 2022

(Rs. in Lakhs)


	Particulars	As at September 30, 2022	As at March 31, 2022
I	ASSETS		
1	Non-current assets		
	(a) Property, plant and equipment		-
	(b) Right to use assets		
	(c) Capital work in progress		
	(d) Long-term loans & Advances	-	-
	(e) Other non-current asset	91.66	91.66
	Total non-current assets (A)	91.66	91.66
2	Current assets		
	(a) Investments	192.72	
	(b) Financial assets		
	(i) Cash and cash equivalents	0.87	208.33
	(ii) Bank Balances other than (i) above	-	-
	(c) Current Tax Asset (Net)	-	-
	(d) Short-term loans & Advances	1.46	-
	(e) Other current assets	-	-
	Total current assets (B)	195.05	208.33
	Total assets (A+B)	286.71	299.99
II	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity share capital	300.00	300.00
	(b) Other equity	(14.54)	(1.01)
	Total equity (A)	285.46	298.99
2	Liabilities		
(i)	Non-current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade Payables	-	-
	(b) Long term liability	-	-
	(c) Deferred tax Liabilities(Net)		
	(d) Other non Current Liabilities		
	Total non-current liabilities (B)	-	-
(ii)	Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	-	-
	(b) Other current liabilities	1.25	1.00
	(c) Current Tax Laibilities (net)	-	-
	Total current liabilities (C)	1.25	1.00
	Total liabilities (D=B+C)	1.25	1.00
	Total equity and liabilities (A+D)	286.71	299.99


For and on behalf of the Board of Directors
Bandaram Pharma Packtech Limited
(Formerly Known as Shiva Medicare Limited)



B. Muniratnam Reddy
Managing Director
DIN No.09487708

Date: 09-11-2022
Place: Hyderabad

Bandaram Pharma Packtech Limited (Formerly Known as Shiva Medicare Limited) CIN: L9309OKA1993PLC159827 Regd Office: 601,5th Floor, Oxford Towers, opp to Leela Palace Hotel, Old Airport Road, Kodihalli Bangalore - 560008			
CONSOLIDATE BALANCE SHEET AS AT 30TH SEPTEMBER 2022 (Amount in lakhs)			
	PARTICULARS	As at September 30, 2022	As at March 31, 2022
I	ASSETS:		
(1)	Non-current assets		
	(a) Property, Plant and Equipment	341.66	282.02
	(b) Right of Use Assets	-	-
	(c) Capital work-in-progress	60.81	-
	(d) Investment Property	-	5.00
	(e) Goodwill	-	-
	(f) Other Intangible Assets	-	-
	(g) Intangible Assets under development	-	-
	(h) Biological Assets	-	-
	(i) Financial assets	-	-
	(i) Investments	-	-
	(ii) Trade Receivables	-	-
	(iii) Loans & Advances	5.00	-
	(iv) Other Financial Assets	-	-
	(j) Deferred tax assets (net)	-	-
	(k) Other non-current assets	93.71	93.71
	SUB TOTAL	501.18	380.73
(2)	Current assets		
	(a) Inventories	381.31	7.43
	(b) Financial assets	-	-
	(i) Investments	-	208.96
	(ii) Trade receivables	184.59	-
	(iii) Cash and cash equivalents	6.22	3.95
	(iv) Bank Balances other than (iii) above	6.60	-
	(v) Loans and advances	119.43	126.97
	(vi) Investments held for Sale	-	-
	(c) Current Tax Asset Net	-	-
	(d) Other current assets	65.16	19.58
	SUB TOTAL	763.30	366.89
	Non-Current Assets Classified as held for Sale	-	-
	TOTAL ASSETS	1,264.48	747.63
II	EQUITY AND LIABILITIES:		
	Equity		
	(a) Equity Share Capital	756.05	706.40
	(b) Other Equity	-	(5.67)
	(ii) Reserves and Surplus	(47.80)	-
	© Share Application money pending allotment	-	-
	Minority Interest	-	-
		708.25	700.73
	Liabilities		
(1)	Non Current Liabilities		
	(a) Financial Liabilities	-	-
	(i) Borrowings	-	-
	(ii) Trade Payables	-	-
	(iii) Other financial liabilities	219.22	34.65
	(b) Provisions	-	-
	(i) Provision for Employee benefit	-	-
	(ii) Others	-	-
	(c) Deferred tax liabilities (Net)	4.54	4.54
	(d) Other non Current Liabilities	-	-
		223.76	39.19
(2)	Current Liabilities		
	(a) Financial Liabilities	-	-
	(i) Borrowings	322.07	-
	(ii) Trade Payables	3.21	4.00
	(iii) Other financial liabilities	-	-
	(b) Other current liabilities	7.19	3.71
	(c) Provisions	-	-
	(d) Current tax liabilities(Net)	-	-
		332.48	7.71
	TOTAL EQUITY AND LIABILITIES	1,264.48	747.63
For and on behalf of the Board of Directors Bandaram Pharma Packtech Limited (Formerly Known as Shiva Medicare Limited)			
			
B. Muniratnam Reddy Director DIN No.09487708			
Place: Hyderabad			
Date: 9-11-2022			

Bandaram Pharma Packtech Limited (Formerly Known as Shiva Medicare Limited) CIN: L93090KA1993PLC159827 Regd Office: 601,5th Floor, Oxford Towers, opp to Leela Palace Hotel, Old Airport Road, Kodihalli Bangalore - 560008 STAND ALONE CASH FLOW STATEMENT		
(Amount in lakhs)		
Particulars	As at September 30, 2022	As at March 31, 2022
Net loss for the period before tax and extraordinary items	(13.53)	(1.01)
Adjustments for:		
Depreciation	-	-
Interest Income	-	-
Interest expense	-	-
Miscellaneous Expenditure under CIRP	-	459.51
Increase in current liabilities	0.25	(114.93)
(Increase) / Decrease in Loans, advances & Other	(194.18)	39.00
Decrease in Current Assets	-	(91.07)
Net Cash used in Operating Activities	(207.46)	291.50
CASH FLOWS FROM INVESTING ACTIVITIES		
Payment towards acquisition of fixed assets	-	10.54
Proceeds / (Repayment) of Loans & advances	-	75.94
Proceeds from long term liabilities	-	(241.97)
Interest received	-	-
Net Cash provided by Investing Activities	-	(155.49)
CASH FLOWS FROM FINANCING ACTIVITIES		
Issue of equity shares	-	72.30
Interest	-	-
Net Cash provided / used by Financing Activities	-	72.30
Net Increase / (Decrease) in Cash & Cash equivalents - (a)	(207.46)	208.31
Opening cash & cash equivalents - (b)	208.32	0.01
Closing cash & cash equivalents - (a) + (b)	0.86	208.32
For and on behalf of the Board of Directors Bandaram Pharma Packtech Limited (Formerly Known as Shiva Medicare Limited)		
 B. Muniratnam Reddy Managing Director DIN No.09487708		
Place: Hyderabad		
Date: 9-11-2022		

Bandaram Pharma Packtech Limited

(Formerly Known as Shiva Medicare Limited)

CIN: L93090KA1993PLC159827

Regd Office: 601,5th Floor, Oxford Towers, opp to Leela Palace Hotel, Old Airport Road, Kodihalli
Bangalore - 560008**CONSOLIDATED CASH FLOW STATEMENT****(Amount in lakhs)**

Particulars	As at September 30, 2022	As at March 31, 2022
Net loss for the period before tax and extraordinary items	-42.13	-5.67
Adjustments for:	-	-
Depreciation	29.45	3.95
Interest Income	-	-
Interest expense	-	-
Miscellaneous Expenditure under CIRP	-	459.51
Increase in current liabilities	324.76	-132.43
(Increase) / Decrease in Loans, advances &Others	-185.18	167.97
Decrease in Current Assets	-413.97	-64.08
Net Cash used in Operating Activities	-287.07	429.26
CASH FLOWS FROM INVESTING ACTIVITIES		
Payment towards acquisition of fixed assets	-149.89	236.90
Proceeds / (Repayment) of Loans & advances	-	75.94
Proceeds from long term liabilities	184.57	-202.78
Interest received	-	-
Net Cash provided by Investing Activities	34.67	110.07
CASH FLOWS FROM FINANCING ACTIVITIES		
Issue of equity shares	49.65	396.20
Interest	-	-
Net Cash provided / used by Financing Activities	49.65	396.20
Net Increase / (Decrease) in Cash & Cash equivalents - (a)	-202.74	208.31
Opening cash & cash equivalents - (b)	208.96	0.65
Closing cash & cash equivalents - (a) + (b)	6.22	208.96

The notes are an integral part of the financial statements

For and on behalf of the Board of Directors
Bandaram Pharma Packtech Limited
(Formerly Known as Shiva Medicare Limited)B. Muniratnam Reddy
Managing Director
DIN No.09487708Place: Hyderabad
Date: 9-11-2022



LIMITED REVIEW REPORT

To,
The Board of Directors,
BANDARAM PHARMA PACKTECH LIMITED

We have reviewed the accompanying statement of Un-audited Financial Results of **BANDARAM PHARMA PACKTECH LIMITED (formerly known as Shiva Medicare Limited)** for the quarter ended **30th September, 2022** attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, as amended.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 is the responsibility of the company management and has been approved by the Board of Directors of the Company. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the Independent auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M M REDDY & CO.,
Chartered Accountants
Firm Regn No 010371S

M Madhusudhana Reddy
Partner
Membership No 213077
UDIN: 22213077BCQIHX1891



Place: Hyderabad
Date: 09-11-2022





Independent Auditor's Review Report on Interim Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

Board of Directors of

M/s. BANDARAM PHARMA PACKTECH LIMITED

We have reviewed the quarterly Consolidated Unaudited Financial Results of **BANDARAM PHARMA PACKTECH LIMITED (formerly known as Shiva Medicare Limited)** ("The Company") and its subsidiaries (Collectively referred to as Group) for the quarter ended 30th September, 2022 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

These quarterly consolidated financial results as well have been prepared on the basis of the consolidated interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these Consolidated financial results based on our audit of such Consolidated interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our review of the Statement in accordance with the standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity," issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Attention is drawn to the statement which states that the Consolidated figures for the Corresponding quarters ended September 30,2021 and June 30, 2022 as reported in the accompanying Statement have been approved by the Parent's Board of Directors, but have not been subjected to review.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

We did not review the interim financial information of Subsidiary company which are included in the consolidated quarterly unaudited financial results, whose consolidated interim financial information reflects, total revenues of VSR Paper and Packaging Limited is Rs. 236.81 Lakhs for the quarter ended 30th September, 2022, total net Loss of VSR Paper and Packaging Limited is Rs. 24.35 Lakhs and total comprehensive income/(loss) of VSR Paper and Packaging Limited is (Rs.24.35) Lakhs for the quarter ended September 30, 2022. These interim financial information has been reviewed by other Auditors whose reports have been furnished to us by management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, based solely on the reports of the other auditors.


In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results:

- I. Include the quarterly financial results of the following entities: -
 - a) VSR Paper and Packaging Limited (Holding 55%)
- II. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard;

For M M REDDY & CO.


Chartered Accountants

Firm Registration No.010371S


M. Madhusudhana Reddy
Partner

Membership No.213077

UDIN: 22213077BCQIWD8265



Place: Hyderabad

Date: 09-11-2022